Cantitate/Preț
Produs
Total produse
Vezi coșul
Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways de Yosef Yarden

Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways: Resistance to Targeted Anti-Cancer Therapeutics, cartea 15

Editat de Yosef Yarden, Moshe Elkabets
en Limba Engleză Hardback – 10 apr 2018
This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 109243 lei  43-57 zile
  Springer International Publishing – 2 feb 2019 109243 lei  43-57 zile
Hardback (1) 109935 lei  43-57 zile
  Springer International Publishing – 10 apr 2018 109935 lei  43-57 zile

Din seria Resistance to Targeted Anti-Cancer Therapeutics

  • 5% Current Applications for Overcoming Resistance to Targeted Therapies
    Preț: 71810 lei
  • 5% Resistance to Proteasome Inhibitors in Cancer: Molecular Mechanisms and Strategies to Overcome Resistance
    Preț: 110721 lei
  • 5% Resistance to Tyrosine Kinase Inhibitors
    Preț: 109610 lei
  • 5% Resistance to Targeted Therapies Against Adult Brain Cancers
    Preț: 110030 lei
  • 5% Molecular Mechanisms of Tumor Cell Resistance to Chemotherapy: Targeted Therapies to Reverse Resistance
    Preț: 109335 lei
  • 5% TRAIL, Fas Ligand, TNF and TLR3 in Cancer
    Preț: 110322 lei
  • 5% Resistance to Molecular Therapies for Hepatocellular Carcinoma
    Preț: 109388 lei
  • 5% Resistance to Targeted Therapies in Breast Cancer
    Preț: 109610 lei
  • 5% Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
    Preț: 84100 lei
  • 5% Resistance to Ibritumomab in Lymphoma
    Preț: 71591 lei
  • 5% Cancer Stem Cell Resistance to Targeted Therapy
    Preț: 71483 lei
  • 5% Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance
    Preț: 109388 lei
  • 5% Resistance to Targeted Therapies in Lymphomas
    Preț: 71225 lei
  • 5% Resistance to Targeted Therapies in Multiple Myeloma
    Preț: 102459 lei
  • 5% Resistance to Targeted ABC Transporters in Cancer
    Preț: 72357 lei
  • 5% Resistance to Photodynamic Therapy in Cancer
    Preț: 72119 lei
  • 5% Resistance to Immunotoxins in Cancer Therapy
    Preț: 72119 lei
  • 5% Resistance of Cancer Cells to CTL-Mediated Immunotherapy
    Preț: 72668 lei
  • 5% Resistance to Aromatase Inhibitors in Breast Cancer
    Preț: 72321 lei
  • 5% Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
    Preț: 71773 lei

Preț: 109935 lei

Preț vechi: 115722 lei
-5% Nou

Puncte Express: 1649
Preț estimativ în valută:
21036€ • 22019$ • 17509£

Carte tipărită la comandă

Livrare economică 31 martie-14 aprilie

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9783319679303
ISBN-10: 3319679309
Pagini: 257
Ilustrații: XX, 242 p. 22 illus. in color.
Dimensiuni: 155 x 235 mm
Greutate: 0.54 kg
Ediția:1st ed. 2018
Editura: Springer International Publishing
Colecția Springer
Seria Resistance to Targeted Anti-Cancer Therapeutics

Locul publicării:Cham, Switzerland

Cuprins

Resistance of colorectal tumors to anti-EGFR antibodies.- Resistance of lung cancer to kinase inhibitors specific to EGFR or ALK.- Mechanisms of action and resistance of trastuzumab in breast cancer.- Mechanisms of resistance to molecular therapies targeting the HGF/MET axis.- RAF, MEK and ERK inhibitors as anti-cancer drugs: intrinsic and acquired resistance as a major therapeutic challenge.- Mechanisms of resistance to PI3K and AKT inhibitors.- Sensitivity and resistance to BH3 mimetics in cancer therapy.- Resistance mechanisms to cyclin-dependent kinase inhibitors.- Resistance to inhibitors of angiogenesis.

Notă biografică

Yosef Yarden, PhD, is Professor, Department of Biological Regulation, The Weizmann Institute of Science, Israel.

Textul de pe ultima copertă

This volume comprehensively covers the multiplicity and diversity of mechanisms underlying patient resistance to currently approved anti-cancer drugs, including tyrosine kinase inhibitors and monoclonal antibodies, blockers of growth factor receptors and their downstream pathways, which play essential functions in cancer progression. Each chapter will cover a specific group of targets and the cognate drugs, along with molecular modes of innate and evolving resistance.

Caracteristici

Comprehensively covers the multiplicity and diversity of mechanisms underlying resistance to the currently approved drugs, both tyrosine kinase inhibitors and monoclonal antibodies, that specifically inhibit growth factor receptors playing driver or survival functions in cancer Examines specific targets and the cognate drugs Evaluates molecular modes of innate and evolving resistance